Some of what you may be missing (or overlooking like so many on these boards) includes:
- Leslie going to the last JPM conference with an "Introduction to Imugene" slide that mentioned HER-Vaxx 4 times and highlighted a 10-year investment in it, a further 9 slides dedicated to HER-Vaxx and its Phase 2 results, only to turn up to this conference without a single expected catalyst in the next two years for HER-Vaxx. Don't you think this may impact on Leslie's credibility and why her claims about CF33 or Azercell may be discounted?
- Leslie never having elicited the slightest BP interest in her 8 years at the helm and in spite of her spending millions on Monil to help her. She has failed to even get free product from a BP for combination trials, let alone any form of collaboration, let alone any form of sponsorship, let alone any form of funding, let alone any form of licensing, let alone any takeover.
- Paul and Leslie having stated on multiple occasions over more than a decade that IMU was a "sell at Phase 2" proposition (including at last year's JPM conference), only to "de-prioritise" the only product that was at Phase 2.
- Paul and Leslie having stated on multiple occasions over more than a decade that IMU was a "sell at Phase 2" proposition (including at last year's JPM conference), only to have IMU make acquisitions and change their narrative to be something else in the 12 months since.
- Paul having recently completed a capital raise at a lower price to the one conducted in 2019, and at a lower price to the multiple capital raises in between.
- Paul engineering the removal of the best scientific brain at Imugene, overseeing a remuneration strike and almost another one, yet still acting as an arrogant dictator at AGMs.
- The biotech world knowing that the one acquisition made from Paul was subsequently binned. So in his biotech career, spanning more than two decades, not a single product he has been associated with has made it to Phase 3, let alone been commercialised either by a company he's associated with or by anyone else.
CF33 has the normal risks associated with any pharmaceutical drug in development, but the track record of Leslie and Paul poses an added risk. Vaxinia is powering through its dose escalations, Professor Fong is excited and the biotech sector is on a strong upswing - what more evidence do people need to acknowledge that IMU's management team is dragging it down?
Presentation at a high-profile US-based investment conference and exposure in one of Australia's high-profile newspapers and the SP of a company that's been listed for 12 years declines from 13c to 11c. How long can anyone keep bleating on about markets not getting it? Is it possible that markets do get it and are simply writing off IMU's chance of commercial success due to the extended failures of its management team?
Expand
(20min delay)